The role of miR-26 in tumors and normal tissues (Review)

Abstract

Abstract. miR-26, a functional miRNA, has received much attention from researchers

MicroRNA-26b Inhibits Hepatitis B Virus Transcription and Replication by Targeting the Host Factor CHORDC1 Protein

“…There is evidence that miR-26b has a role in the development of normal tissues and many diseases (20). We determined that miR-26b acts as a host restriction factor to attenuate HBV replication in hepatoma cells.…”

“…Respiratory syncytial virus infection of A549 cells induces miR-26b expression, and it may affect the antiviral host response (19). The miR-26b expression is frequently abnormal in tumors, indicating that miR-26b plays a significant role in cancer development (20). The miR-26b level is significantly up-regulated in bladder cancer (21), whereas it is down-regulated in liver cancer (22), colorectal cancer (23), and human breast cancer (24,25).…”

“…The human miR-26 family is composed of miR-26a-1, miR26a-2, and miR-26b (20). Hsa-miR-26a is the mature form of miR-26a-1 and miR-26a-2.…”

Long non-coding RNA MINCR promotes gallbladder cancer progression through stimulating EZH2 expression

“…We then combined the prediction results by online software (miRanda) and proposed a hypothesis that miR-26a-5p might be the target of MINCR, dual luciferase assays then confirmed that MINCR is directly bound to miR-26a-5p. MiR-26a is an important regulator in tumorigenesis and cancer progression, exerting either promoting or inhibitory effects on cancers based on tumor types [36]. For example, miR-26a enhanced miRNA biogenesis by targeting lin28B and Zcchc11 to suppress tumor growth and metastasis, including melanomas and prostate and liver cancers [37].…”

miR-26a Promoted by Interferon-Alpha Inhibits Hepatocellular Carcinoma Proliferation and Migration by Blocking EZH2

“…The microRNA (miR)-26 family is composed of miR-26a-1, miR-26a-2, and miR-26b located on chromosomes 3, 12, and 2, respectively (Gao and Liu, 2011;Han et al, 2012). miR-26a is consistently downregulated in a wide range of malignant tumors, such as HCC, nasopharyngeal carcinoma, lung cancer, and breast cancer (Lu et al, 2011;Yu et al, 2013).…”